Publication:
Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient.

dc.contributor.authorRomero-Laorden, N
dc.contributor.authorPiñeiro-Yañez, E
dc.contributor.authorGutierrez-Pecharroman, A
dc.contributor.authorPacheco, M I
dc.contributor.authorCalvo, E
dc.contributor.authorAl-Shahrour, F
dc.contributor.authorCastro, E
dc.contributor.authorOlmos, D
dc.date.accessioned2023-01-25T09:45:35Z
dc.date.available2023-01-25T09:45:35Z
dc.date.issued2017
dc.identifier.doi10.1093/annonc/mdx067
dc.identifier.essn1569-8041
dc.identifier.pmid28453706
dc.identifier.unpaywallURLhttps://doi.org/10.1093/annonc/mdx067
dc.identifier.urihttp://hdl.handle.net/10668/11146
dc.issue.number5
dc.journal.titleAnnals of oncology : official journal of the European Society for Medical Oncology
dc.journal.titleabbreviationAnn Oncol
dc.language.isoen
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.organizationHospital Universitario Virgen de la Victoria
dc.organizationHospital Universitario Regional de Málaga
dc.page.number1158-1159
dc.pubmedtypeCase Reports
dc.pubmedtypeLetter
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rights.accessRightsopen access
dc.subject.meshAged
dc.subject.meshBRCA2 Protein
dc.subject.meshBenzimidazoles
dc.subject.meshGenes, BRCA2
dc.subject.meshGerm-Line Mutation
dc.subject.meshHumans
dc.subject.meshLoss of Heterozygosity
dc.subject.meshMale
dc.subject.meshPoly(ADP-ribose) Polymerase Inhibitors
dc.subject.meshProstatic Neoplasms, Castration-Resistant
dc.titleSomatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number28
dspace.entity.typePublication

Files